The use of prognostic factors in metastatic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 12, 2015, Pages 509-516

  Li, Haoran ^a   Samawi, Haider ^a   Heng, Daniel Y C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

International Metastatic Renal Cell Carcinoma Database Consortium; Prognostic factor; Renal cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; TEMSIROLIMUS; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; NEPHRECTOMY; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT PLANNING; CARCINOMA, RENAL CELL; METASTASIS; MORTALITY; PROGNOSIS; SECONDARY; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84960465951     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.08.003     Document Type: Review

References (72)

1. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
2. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
3. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., Malhi S., Wood L., Elson P., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841.
4. Maroto P., Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 2014, 20:2060-2071.
5. Tang P.A., Vickers M.M., Heng D.Y. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 2011, 25:871-891.
6. Leibovich B.C., Han K.R., Bui M.H., Pantuck A.J., Dorey F.J., Figlin R.A., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 98:2566-2575.
7. Patil S., Figlin R.A., Hutson T.E., Michaelson M.D., Negrier S., Kim S.T., et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011, 22:295-300.
8. Negrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002, 13:1460-1468.
9. Iacovelli R., Farcomeni A., Sternberg C.N., Carteni G., Milella M., Santoni M., et al. Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. J Urol 2015, 193:1905-1910.
10. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
11. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
12. Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
13. Schutz F.A., Xie W., Donskov F., Sircar M., McDermott D.F., Rini B.I., et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014, 65:723-730.
14. Jeppesen A.N., Jensen H.K., Donskov F., Marcussen N., von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010, 102:867-872.
15. Suppiah R., Shaheen P.E., Elson P., Misbah S.A., Wood L., Motzer R.J., et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006, 107:1793-1800.
16. Blay J.Y., Favrot M., Rossi J.F., Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993, 82:2261-2262.
17. O'Byrne K.J., Dobbs N., Propper D., Smith K., Harris A.L. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999, 353:1494-1495.
18. Symbas N.P., Townsend M.F., El-Galley R., Keane T.E., Graham S.D., Petros J.A. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000, 86:203-207.
19. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988, 48:7310-7313.
20. Choueiri T.K., Garcia J.A., Elson P., Khasawneh M., Usman S., Golshayan A.R., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
21. Atzpodien J., Royston P., Wandert T., Reitz M. Group DGCRCC-IT. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003, 88:348-353.
22. Ljungberg B., Grankvist K., Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76:1435-1439.
23. Yasuda Y., Saito K., Yuasa T., Kitsukawa S., Urakami S., Yamamoto S., et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2013, 18:884-889.
24. Alimohamed NS. Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma. Genitourinary Cancers Symposium. Orlando, FL; 2015.
25. Heng D.Y., Xie W., Regan M.M., Harshman L.C., Bjarnason G.A., Vaishampayan U.N., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013, 14:141-148.
26. Patard J.J., Leray E., Rioux-Leclercq N., Cindolo L., Ficarra V., Zisman A., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23:2763-2771.
27. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
28. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
29. Manola J., Royston P., Elson P., McCormack J.B., Mazumdar M., Negrier S., et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 2011, 17:5443-5450.
30. Vickers M.M., Al-Harbi H., Choueiri T.K., Kollmannsberger C., North S., MacKenzie M., et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2013, 11:311-315.
31. McKay R.R., Kroeger N., Xie W., Lee J.L., Knox J.J., Bjarnason G.A., et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014, 65:577-584.
32. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
33. Motzer R.J., Bacik J., Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004, 10. 6302S-3S.
34. Ko J.J., Choueiri T.K., Rini B.I., Lee J.L., Kroeger N., Srinivas S., et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 2014, 110:1917-1922.
35. Vickers M.M., Choueiri T.K., Rogers M., Percy A., Finch D., Zama I., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, 76:430-434.
36. Ko J.J., Xie W., Heng D.Y.C., Kroeger N., Lee J.-L., Rini B.I., et al. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). J Clin Oncol 2014, 32. (suppl 4; abstr 398).
37. Ko J.J., Xie W., Kroeger N., Lee J.L., Rini B.I., Knox J.J., et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015, 16:293-300.
38. Kroeger N., Choueiri T.K., Lee J.L., Bjarnason G.A., Knox J.J., MacKenzie M.J., et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 2014, 65:1086-1092.
39. Heng D.Y., Choueiri T.K., Rini B.I., Lee J., Yuasa T., Pal S.K., et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014, 25:149-154.
40. Kroeger N., Xie W., Lee J.L., Bjarnason G.A., Knox J.J., Mackenzie M.J., et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013, 119:2999-3006.
41. Harshman L.C., Xie W., Bjarnason G.A., Knox J.J., MacKenzie M., Wood L., et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012, 13:927-935.
42. Bianchi M., Becker A., Hansen J., Trinh Q.D., Tian Z., Abdollah F., et al. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. BJU Int 2013, 111:E283-E289.
43. Matsubara N., Mukai H., Naito Y., Itoh K., Komai Y., Sakai Y. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma. Urology 2013, 82:118-123.
44. Park I., Lee J.L., Ahn J.H., Lee D.H., Lee K.H., Jeong I.G., et al. Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol 2014, 140:1421-1428.
45. Rini B.I., Dorff T.B., Elson P., Suarez C., Humbert J., Pyle L., et al. A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. J Clin Oncol 2014, 32. 5s(suppl; abstr 4520).
46. Rini BI. Delayed initiation of systemic therapy in metastatic RCC; 2015.
47. Molina A.M., Motzer R.J. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011, 16(Suppl. 2):45-50.
48. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
49. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
50. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R., European Organisation for Research and Treatment of Cancer (EORTC), et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970.
51. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076.
52. Choueiri T.K., Xie W., Kollmannsberger C., North S., Knox J.J., Lampard J.G., et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185:60-66.
53. Heng D.Y., Wells J.C., Rini B.I., Beuselinck B., Lee J.L., Knox J.J., et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014, 66:704-710.
54. Culp S.H., Tannir N.M., Abel E.J., Margulis V., Tamboli P., Matin S.F., et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer 2010, 116:3378-3388.
55. Westesson.K.E., Klink.J.C., Rabets.J.C., Fergany.A.F., Klein.E.A., Stephenson.A.J., et al. Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. Urology 2014, 84:1414-1419.
56. ClinicalTrials.gov. Clinical trial to assess the importance of nephrectomy (CARMENA); 2015.
57. ClinicalTrials.gov. Phase 3 trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (RCC) (ADAPT); 2015.
58. Figlin.R.A., Wood C.G. Enrollment insights in the synchronous mRCC population: an update from the ongoing ADAPT* phase 3 study experience. J Clin Oncol 2014, 32. 5s(suppl; abstr TPS4599).
59. ClinicalTrials.gov. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214); 2015.
60. Iacovelli R., Carteni G., Sternberg C.N., Milella M., Santoni M., Di Lorenzo G., et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013, 49:2134-2142.
61. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
62. Pena-Llopis S., Vega-Rubin-de-Celis S., Liao A., Leng N., Pavia-Jimenez A., Wang S., et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012, 44:751-759.
63. Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J 2013, 19:324-332.
64. Hsieh.J., Chen.D., Wang.P., Chen.Y., Redzematovic.A., Marker M., et al. Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): results from RECORD-3. J Clin Oncol 2015, 33. (suppl; abstr 4509).
65. Kapur P., Pena-Llopis S., Christie A., Zhrebker L., Pavia-Jimenez A., Rathmell W.K., et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013, 14:159-167.
66. Carosella E.D., Ploussard G., LeMaoult J., Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015, (15):197-199. [PII: S0302-2838].
67. Rausch S., Kruck S., Stenzl A., Bedke J. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncol 2014, 10:937-948.
68. Figlin R.A. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. Immunotherapy 2014, 6:261-268.
69. Brown S.D., Warren R.L., Gibb E.A., Martin S.D., Spinelli J.J., Nelson B.H., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014, 24:743-750.
70. Raman.R., Vaena.D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. BioMed Res Int 2015, 2015. 367354.
71. Characiejus D., Jacobs J.J.L., Pašukoniene V., Kazlauskaite N., Danilevičiute V., Mauricas.M., et al. Prediction of response in cancer immunotherapy. Anticancer Res 2011, 31:639-647.
72. Rini B.I., Cohen D.P., Lu D.R., Chen I., Hariharan S., Gore M.E., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.